Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[225Ac]-FPI-2068 in Advanced Solid Tumours
NCT06147037Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of FPI-2068 in solid tumor, colorectal carcinoma (CRC), head and neck squamous cell carcinoma (HNSCC) and 4 more, sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of [111In]-FPI-2107, FPI-2053, and [225Ac]-FPI-2068 up to 5 years, Radiation dose of [111In]-FPI-2107 and [225Ac]-FPI-2068 at 56 days and 2 more. Started Jul 2024; status: active, not recruiting.
02
Drugs
FPI-2068
03
Conditions
solid tumorcolorectal carcinoma (CRC)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06147037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06147037.